|Description||N-Despropyl-macitentan, an active metabolite of Macitentan, is a dual ET receptor antagonist with longer half-life than Macitentan. It has been proved to be effective in the treatment of ulmonary arterial hypertension.|
|Solubility||DMSO: ≥ 46 mg/mL|
|Application||N-Despropyl-macitentan is a dual ET receptor antagonist with longer half-life than Macitentan.|
|Shelf Life||As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly|
Sitaxentan sodium inhibits ET-1-induced stimulation of phosphoinositide turnover with a Ki of 0.69 nM and a pA2 of 8.0.
Macitentan n-butyl analogue
Macitentan n-butyl analogue is a derivative of Macitentan, which is an antagonist/blocker of endothelin receptors on blood vessels and smooth muscle.
BMS 182874 Hydrochloride
This active molecular is a selective non-peptide Endothelin ETA receptor antagonist. It displays more than 1000-fold selectivity over ETB receptors (Ki of 48 nM...
N-Despropyl-macitentan, an active metabolite of Macitentan, is a dual ET receptor antagonist with longer half-life than Macitentan. It has been proved to be eff...
T-0201 has been found to be an Endothelin A receptor antagonist that could be used as as anti-ischaemic agent and was once studied in heart failure and pulmonar...
RO462005 is an endothelin receptor selective agonist.
Ambrisentan, a highly selective antagonist of the endothelin-1 type A receptor with IC50 of 18 nM, is indicated for the treatment of pulmonary arterial hyperten...
BMS-248360 is a first orally active generation dual action receptor antagonist. BMS-248360 antagonized both Ang II AT1 and endothelin ETA receptors (AT1 IC50 = ...
Endothelin 1 swine, human
Endothelin 1 (swine, human), a vasoconstrictor increased in plasma and explants of patients with uterine leiomyomas, is a synthetic peptide with the sequence of...
Clazosentan, also called as AXV 034, Ro 61-1790 or VML 588, a novel endothelin A antagonist, improves cerebral blood flow and behavior after traumatic brain inj...
Fandosentan potassium is an endothelin A antagonist developed for the treatment of pulmonary hypertension.
Tak-044 has been found to be an endothelin receptor antagonist that was once studied against some sort of liver disorders and subarachnoid haemorrhage.
Atrasentan hydrochloride is the hydrochloride salt form of Atrasentan. Atrasentan, also called as ABT-627, is a selective and orally available antagonist of ETA...
Zibotentan (ZD4054)is an orally administered, potent and specific ETA-receptor (endothelin A receptor) antagonist (IC50 = 21 nM).
BMS-187308, a sulfonamide derivative, has been found to be an endothelin-A (ETA) antagonist that was once studied about its activity against pressor effect in r...
BMS-193884, an oxazol derivative, has been found to be an endothelin A receptor antagonist and was once studied in the treatmen of heart failure.
Macitentan is an orally available dual endothelin receptor (ETR) antagonist with potential antihypertensive and antineoplastic activity.
SB-209670 has been found to be an endothelin receptor antagonist that was once studied against arrhythmias and hypertension.
FR 139317 is a selective Endothelin A receptor antagonist originated by Fujisawa. (Ki values are 1 nM and 7.3 μM at ETA and ETB subtypes respectively). No devel...
Edonentan, also known as BMS-207940, is a very potent and selective ETA endothelin receptor antagonist (Ki= 10 pM) that shows 80000-fold selective for ETA vs ET...